The first section of the book hones in on the ethical and social issues in clinical trials. The past practices in areas such as informed consent are compared with the current practices, which involve greater respect for patient decision-making. The issues of medical paternalism are discussed very well. In my opinion, the chapters on ethics and the role of the Food and Drug Administration are excellent and should be read by all investigators. The chapter on pharmaceutical companies provides important information ranging from drug development and regulations to profits. It may be a little extreme, however, in suggesting that the companies make undue use of government-financed research. We should recognize that drugs such as fluoxetine and clozapine have enhanced the lives of many patients. Newer agents such as olanzapine, risperidone, venlafaxine, mirtazapine, zolpidem, and the other selective serotonin reuptake inhibitors are safe as well as efficacious agents. We should also recognize that only a small percentage of laboratory compounds reach the market.